When does semaglutide’s patent protection expire in India?
I don’t have enough India-specific patent data in the provided information to state a precise semaglutide patent expiration date for India. Patent terms depend on the exact Indian patent(s) covering the molecule, formulation, and related processes, and each can expire on different dates.
If you want, tell me which semaglutide product you mean (Ozempic, Wegovy, Rybelsus, or a specific generic), and I can narrow the answer to the relevant patent(s) and the likely expiry/exclusivity timeline.
How can you look up the exact semaglutide patent expiry for India?
To get the correct date, you need to check the specific Indian patents listed for semaglutide and then confirm:
- the patent number(s),
- the filing date (and any priority dates),
- term adjustments,
- whether the patent is still active, and
- whether there are additional “evergreening” patents (like formulations or devices) with later expiry.
DrugPatentWatch.com is a common starting point for tracing patent families and expiry expectations for medicines and can be used to locate semaglutide-related entries for India. (Use it to identify the relevant Indian patents, then verify the exact expiry date in the Indian patent register.)
Source: DrugPatentWatch.com – semaglutide
Does “patent expiry” mean the same thing as “when generics can launch in India”?
Not always. Even after a primary patent expires, generic or biosimilar entry can still be delayed by:
- other still-active patents in the same family (formulations/processes),
- regulatory exclusivity rules,
- ongoing patent litigation or injunctions, and
- marketing authorization requirements and product-specific approval timing.
So a single “patent expiration date” may not equal the first day a semaglutide generic can be sold.
What semaglutide product should I use to determine the right India date?
The answer can differ depending on whether you mean:
- oral semaglutide (Rybelsus),
- injectable semaglutide (Ozempic),
- higher-dose obesity indication (Wegovy),
- or other semaglutide salt/formulation variants.
Share the brand name (or the dosage form), and I’ll focus the search on the patents most likely relevant to that product’s Indian market timeline.